Cargando…

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unseld, Matthias, Fischöder, Sebastian, Jachs, Mathias, Drimmel, Magdalena, Siebenhüner, Alexander, Bianconi, Daniela, Kieler, Markus, Puhr, Hannah, Minichsdorfer, Christoph, Winder, Thomas, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356853/ https://www.ncbi.nlm.nih.gov/pubmed/32517383 http://dx.doi.org/10.3390/jcm9061772

Ejemplares similares

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
por: Kieler, Markus, et al.
Publicado: (2017)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior
por: Bianconi, Daniela, et al.
Publicado: (2022)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Bianconi, Daniela, et al.
Publicado: (2017)

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
por: Balendran-Braun, Sukirthini, et al.
Publicado: (2021)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

Screening for post‐traumatic stress disorders in 1017 cancer patients and correlation with anxiety, depression, and distress
por: Unseld, Matthias, et al.
Publicado: (2019)

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology
por: Prager, Gerald W., et al.
Publicado: (2019)

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
por: Fuchs, Hannah, et al.
Publicado: (2018)

Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial
por: Mair, Maximilian J., et al.
Publicado: (2023)

New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease
por: Kieler, Markus, et al.
Publicado: (2016)

IL-6-mediated migration of human metastatic melanoma cells is reduced by simvastatin treatment
por: Wasinger, Christine, et al.
Publicado: (2012)

CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior
por: Poettler, Marina, et al.
Publicado: (2013)

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer
por: Puhr, Hannah Christina, et al.
Publicado: (2023)

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer
por: Bartl, Thomas, et al.
Publicado: (2023)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells
por: Minichsdorfer, Christoph, et al.
Publicado: (2015)

Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines
por: Otahal, Alexander, et al.
Publicado: (2020)

What have we learnt from the past – would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
por: Stiefel, Rahel, et al.
Publicado: (2023)

SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey
por: Prager, G., et al.
Publicado: (2021)

Clinical risk factors for ascites in metastatic pancreatic cancer
por: Berger, J.M., et al.
Publicado: (2023)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
por: Akhoundova Sanoyan, Dilara, et al.
Publicado: (2020)

Long-lasting response to third-line chemotherapy in metastatic pancreatic cancer
por: Tavares, Alda, et al.
Publicado: (2020)

Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma – an Austrian expert consensus statement
por: Taghizadeh, Hossein, et al.
Publicado: (2023)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2019)

Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done
por: Mare, Marzia, et al.
Publicado: (2022)

Statins induce apoptosis in human melanoma cells via multiple pathways
por: Minichsdorfer, Christoph, et al.
Publicado: (2008)

Cytokine signalling in human melanoma cells determines susceptability to statin-induced apoptosis
por: Minichsdorfer, Christoph, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oa4862ss1indo9nktfpi5g36bd